Financial Ratios Arecor Therapeutics plc
Equities
AREC
GB00BMWLM973
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
58.50 GBX | 0.00% | 0.00% | -20.41% |
Jan. 10 | Arecor Therapeutics shares tumble as plans Tetris wind-down | AN |
Jan. 10 | Arecor Therapeutics to Shutter Tetris Pharma Unit; Ends License Deal with Xeris | MT |
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Profitability | ||||||
Return on Assets | -47.47 | -49.89 | -29.64 | -30.63 | -30.88 | |
Return on Total Capital | -61.88 | -69.84 | -34.67 | -35.8 | -41.54 | |
Return On Equity % | -99.68 | -138.25 | -63.85 | -51.44 | -63.41 | |
Return on Common Equity | -99.68 | -138.25 | -63.85 | -51.44 | -63.41 | |
Margin Analysis | ||||||
Gross Profit Margin % | 100 | 100 | 100 | 100 | 100 | |
SG&A Margin | 84.94 | 96.7 | 206.3 | 223.93 | 194.9 | |
EBITDA Margin % | -138.07 | -196.75 | -509.59 | -426.97 | -194.18 | |
EBITA Margin % | -141.72 | -201.44 | -515.46 | -431.46 | -198.51 | |
EBIT Margin % | -142.16 | -201.93 | -516.15 | -435.25 | -200.63 | |
Income From Continuing Operations Margin % | -115.79 | -162.13 | -532.73 | -385.35 | -187.05 | |
Net Income Margin % | -115.79 | -162.13 | -532.73 | -385.35 | -187.05 | |
Net Avail. For Common Margin % | -115.79 | -162.13 | -532.73 | -385.35 | -187.05 | |
Normalized Net Income Margin | -88.97 | -129.31 | -323.73 | -269.74 | -121.65 | |
Levered Free Cash Flow Margin | -262.59 | -87.04 | -310.91 | -297.18 | -65.62 | |
Unlevered Free Cash Flow Margin | -260.59 | -84.02 | -309.73 | -296.5 | -65.41 | |
Asset Turnover | ||||||
Asset Turnover | 0.2 | 0.4 | 0.09 | 0.11 | 0.25 | |
Fixed Assets Turnover | 1.89 | 5.06 | 3.29 | 4.12 | 5.47 | |
Receivables Turnover (Average Receivables) | 1.42 | 5.9 | 2.93 | 1.64 | 3.12 | |
Short Term Liquidity | ||||||
Current Ratio | 3.78 | 2.71 | 9.05 | 4.69 | 2.17 | |
Quick Ratio | 3.75 | 2.67 | 8.77 | 4.38 | 1.96 | |
Operating Cash Flow to Current Liabilities | -0.44 | -1.32 | -2.4 | -2.89 | -1.13 | |
Days Sales Outstanding (Average Receivables) | 257.17 | 62.05 | 124.5 | 222.3 | 117.01 | |
Long Term Solvency | ||||||
Total Debt/Equity | 4.93 | 257.87 | 1.25 | 1.65 | 3.55 | |
Total Debt / Total Capital | 4.7 | 72.06 | 1.23 | 1.62 | 3.43 | |
LT Debt/Equity | 1.88 | 244.27 | 0.57 | 0.49 | 2.31 | |
Long-Term Debt / Total Capital | 1.79 | 68.26 | 0.56 | 0.48 | 2.23 | |
Total Liabilities / Total Assets | 25.49 | 81.94 | 11.34 | 19.8 | 38.04 | |
EBIT / Interest Expense | -205.66 | -41.81 | -271.68 | -402.27 | -611.67 | |
EBITDA / Interest Expense | -194.07 | -39.75 | -263.91 | -389.23 | -579.2 | |
(EBITDA - Capex) / Interest Expense | -196.54 | -40.39 | -267.05 | -400.73 | -589.27 | |
Total Debt / EBITDA | -0.06 | -0.61 | -0.04 | -0.03 | -0.04 | |
Net Debt / EBITDA | 1.15 | 0.28 | 3.11 | 1.24 | 0.74 | |
Total Debt / (EBITDA - Capex) | -0.06 | -0.6 | -0.04 | -0.03 | -0.04 | |
Net Debt / (EBITDA - Capex) | 1.13 | 0.27 | 3.08 | 1.2 | 0.73 | |
Growth Over Prior Year | ||||||
Total Revenues, 1 Yr. Growth % | -44.62 | -10.23 | -31.8 | 107.51 | 90.3 | |
Gross Profit, 1 Yr. Growth % | -44.62 | -10.23 | -31.8 | 107.51 | 90.3 | |
EBITDA, 1 Yr. Growth % | 111.65 | 27.93 | 76.68 | 73.87 | -12.44 | |
EBITA, 1 Yr. Growth % | 104.89 | 27.61 | 74.53 | 73.7 | -11.43 | |
EBIT, 1 Yr. Growth % | 104.26 | 27.52 | 74.36 | 74.99 | -11.28 | |
Earnings From Cont. Operations, 1 Yr. Growth % | 117.58 | 25.71 | 124.16 | 50.11 | -7.62 | |
Net Income, 1 Yr. Growth % | 117.58 | 25.71 | 124.16 | 50.11 | -7.62 | |
Normalized Net Income, 1 Yr. Growth % | 101.26 | 30.48 | 70.79 | 72.91 | -13.19 | |
Diluted EPS Before Extra, 1 Yr. Growth % | 57.58 | 22 | 58.12 | 19.49 | -12.71 | |
Accounts Receivable, 1 Yr. Growth % | 62.11 | -84.25 | 812.82 | 211.1 | 241.57 | |
Inventory, 1 Yr. Growth % | - | - | - | - | -31.83 | |
Net Property, Plant and Equip., 1 Yr. Growth % | -19.49 | 27.18 | -12.77 | 155.49 | -0.48 | |
Total Assets, 1 Yr. Growth % | 163.75 | -0.51 | 388.35 | 4.03 | -29.35 | |
Tangible Book Value, 1 Yr. Growth % | 582.02 | -76.73 | 2.42K | -24.12 | -55.66 | |
Common Equity, 1 Yr. Growth % | 528.92 | -75.88 | 2.3K | -5.9 | -45.42 | |
Cash From Operations, 1 Yr. Growth % | 408.51 | 304.67 | 193.48 | 97.8 | -45.82 | |
Capital Expenditures, 1 Yr. Growth % | 466.13 | 61.91 | 32.69 | 333.33 | -49.5 | |
Levered Free Cash Flow, 1 Yr. Growth % | - | - | 143.59 | 98.34 | -57.52 | |
Unlevered Free Cash Flow, 1 Yr. Growth % | - | - | 151.37 | 98.65 | -57.58 | |
Compound Annual Growth Rate Over Two Years | ||||||
Total Revenues, 2 Yr. CAGR % | - | - | -21.75 | 18.96 | 98.72 | |
Gross Profit, 2 Yr. CAGR % | - | - | -21.75 | 18.96 | 98.72 | |
EBITDA, 2 Yr. CAGR % | - | - | 50.34 | 75.27 | 22.67 | |
EBITA, 2 Yr. CAGR % | - | - | 49.24 | 74.11 | 23.32 | |
EBIT, 2 Yr. CAGR % | - | - | 49.11 | 74.67 | 23.9 | |
Earnings From Cont. Operations, 2 Yr. CAGR % | - | - | 67.85 | 83.43 | 17.75 | |
Net Income, 2 Yr. CAGR % | - | - | 67.85 | 83.43 | 17.75 | |
Normalized Net Income, 2 Yr. CAGR % | - | - | 49.27 | 71.84 | 21.82 | |
Diluted EPS Before Extra, 2 Yr. CAGR % | - | - | 38.88 | 37.45 | 2.13 | |
Accounts Receivable, 2 Yr. CAGR % | - | - | 19.66 | 432.89 | 78.48 | |
Net Property, Plant and Equip., 2 Yr. CAGR % | - | - | 5.42 | 49.29 | 59.46 | |
Total Assets, 2 Yr. CAGR % | - | - | 120.43 | 125.4 | -14.27 | |
Tangible Book Value, 2 Yr. CAGR % | - | - | 142.03 | 336.96 | -41.99 | |
Common Equity, 2 Yr. CAGR % | - | - | 140.46 | 374.89 | -28.33 | |
Cash From Operations, 2 Yr. CAGR % | - | - | 244.66 | 140.94 | 3.52 | |
Capital Expenditures, 2 Yr. CAGR % | - | - | 46.16 | 139.79 | 47.93 | |
Levered Free Cash Flow, 2 Yr. CAGR % | - | - | - | 119.81 | -8.71 | |
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | - | - | 123.46 | -8.67 | |
Compound Annual Growth Rate Over Three Years | ||||||
Total Revenues, 3 Yr. CAGR % | - | - | - | 8.31 | 39.13 | |
Gross Profit, 3 Yr. CAGR % | - | - | - | 8.31 | 39.13 | |
EBITDA, 3 Yr. CAGR % | - | - | - | 57.8 | 38.53 | |
EBITA, 3 Yr. CAGR % | - | - | - | 56.99 | 38.46 | |
EBIT, 3 Yr. CAGR % | - | - | - | 57.28 | 38.84 | |
Earnings From Cont. Operations, 3 Yr. CAGR % | - | - | - | 61.72 | 45.94 | |
Net Income, 3 Yr. CAGR % | - | - | - | 61.72 | 45.94 | |
Normalized Net Income, 3 Yr. CAGR % | - | - | - | 56.77 | 36.34 | |
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | - | 32.09 | 18.15 | |
Accounts Receivable, 3 Yr. CAGR % | - | - | - | 64.54 | 207.5 | |
Net Property, Plant and Equip., 3 Yr. CAGR % | - | - | - | 41.61 | 30.41 | |
Total Assets, 3 Yr. CAGR % | - | - | - | 71.62 | 53.11 | |
Tangible Book Value, 3 Yr. CAGR % | - | - | - | 64.42 | 103.81 | |
Common Equity, 3 Yr. CAGR % | - | - | - | 75.89 | 130.89 | |
Cash From Operations, 3 Yr. CAGR % | - | - | - | 186.42 | 46.52 | |
Capital Expenditures, 3 Yr. CAGR % | - | - | - | 109.97 | 42.67 | |
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | - | - | 26.62 | |
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | - | - | 27.99 |
- Stock Market
- Equities
- AREC Stock
- Financials Arecor Therapeutics plc
- Financial Ratios